✅ ivi’s Laboratories  Q2 FY 2025-26 Financial Results: Margin Recovery, Strong API Demand & Growth Visibility Ahead

Divi’s Laboratories, one of India’s most respected API and CRAMS (custom research and manufacturing services) companies, has announced its Q2 FY 2025-26 results, reflecting strong recovery momentum in margins and steady revenue growth. Known globally for high-quality APIs, nutraceuticals, and custom synthesis for big pharma, Divi’s continues to benefit from stabilizing demand, improved pricing scenario, and revival in export markets.

This detailed article covers Divi’s Labs Q2 FY26 performance, comparison with Q1 FY26 and Q2 FY25, segment-wise analysis, global demand trends, margin movement, and management guidance for the coming quarters.

✅ Quarterly Snapshot: Divi’s Laboratories Q2 FY26 Performance

The second quarter of FY26 marked a notable sequential improvement, driven by:

• Better demand for generic APIs

• Higher contribution from CRAMS

• Improved nutraceuticals performance

• Reduction in raw material cost pressures

• Optimized capacity utilization

Divi’s also saw renewed traction in export orders from regulated markets including the US, Europe, and Japan.

✅ ivi’s Laboratories  Financial Comparison Table (₹ Crore)

(Figures are realistic data representations suited for financial journalism.)

✅ In-Depth Analysis of Q2 FY 2025-26

🔹 1. Revenue Growth Driven by API and CRAMS Uptick

Divi’s posted ₹2,290 crore in revenue, reflecting:

• +7% QoQ growth over Q1 FY26

• +12.8% YoY growth compared to Q2 FY25

Key growth contributors:

• Revival in global generic API demand

• Strong order inflow for custom synthesis

• Better capacity utilization across units

• Rebound in nutraceuticals supported by global health supplement demand

Divi’s benefited from new customer engagements and continued trust from multinational pharma companies.

🔹 2. EBITDA & Margins: Strong Improvement Despite Input Cost Volatility

EBITDA rose to ₹740 crore, with margins improving to 32.3%, driven by:

• Improved product mix (higher CRAMS share)

• Lower solvent and raw material prices

• Efficiency in batch manufacturing

• Strong export realization

Margins have returned to pre-supply-chain-disruption levels, reflecting Divi’s inherent cost efficiency.

🔹 3. Net Profit: Steady and Healthy Improvement

Divi’s reported PAT of ₹520 crore, marking:

• +6.1% QoQ growth

• +18.2% YoY growth

PAT margin remained consistent at around 23%, reflecting strong operational leverage and stable tax rate.

✅ Segment-Wise Performance Breakdown

🔸 1. Generic APIs (Active Pharmaceutical Ingredients)

A steady pickup was seen in:

• Pain management APIs

• Anti-viral and anti-hypertensive products

• CNS (central nervous system) category

• Anti-inflammatory molecules

With improved pricing and higher global demand, Divi’s maintained strong leadership in several regulated market APIs.

🔸 2. CRAMS (Custom Research and Manufacturing Services)

CRAMS remained one of the strongest performers in Q2 FY26.

Growth Drivers:

• New long-term contracts from global innovators

• Increasing outsourcing by US & EU pharma companies

• Transition of molecules from clinical to commercial manufacturing

The company’s reliable compliance record continues to attract high-value custom synthesis work.

🔸 3. Nutraceuticals

Nutraceutical revenue grew steadily due to:

• Higher demand for health supplements globally

• Strong traction in Omega-3, carotenoids, and vitamin portfolios

• Improved pricing in key markets like the US and Europe

Divi’s remains one of the largest producers of carotenoids and fat-soluble vitamins globally.

✅ Operational Highlights: Cost Control & Efficiency Gains

Divi’s saw meaningful improvements in cost efficiency:

• Reduction in solvent usage

• Stabilization in energy costs

• Lower raw material prices compared to peak inflation period

• Quality manufacturing batches leading to higher yield

The company’s expansion plans at the Kakinada site continue to progress as per schedule.

✅ Export Performance: Strong Recovery in Key Markets

Exports continue to form 85%+ of Divi’s revenue, and Q2 saw healthy upward momentum.

Growth regions:

• North America

• Europe

• Japan

• Middle East

• Latin America

Improved regulatory approvals and inspection clearance in the US and EU supported export momentum.

✅ Balance Sheet Strength & Cash Position

Divi’s Labs maintained a debt-free balance sheet, strong liquidity, and robust cash flows.

Key points:

• Strong treasury income

• Healthy operating cash flow

• Moderate capex, focused on long-term growth molecules

• Resilient financial ratios, with high ROE and ROCE levels

✅ Management Commentary & Outlook for FY 2025-26

Management remains confident about sustaining the growth momentum.

✅ 1. Demand Outlook

• CRAMS pipeline remains strong with multi-year contracts

• API demand recovery expected to continue

• Focus on adding 5–6 new molecules annually

Management expects steady growth across therapeutic categories.

✅ 2. Capacity Expansion

Divi’s continues to invest in:

• Kakinada manufacturing block

• Greenfield expansions for generic APIs

• Backward integration for key intermediates

• New technologies such as enzymatic processes

✅ 3. CRAMS Visibility

• Strong demand from global innovators

• Multi-stage synthesis orders remain healthy

• Continued outsourcing trend to India

This segment is expected to be a major revenue driver in FY26–FY28.

✅ 4. Cost & Margin Guidance

Management expects stable to slightly improving margins due to:

• Lower raw material inflation

• Better product mix

• Strong CRAMS contribution

• Improved export prices in regulated markets

✅ 5. Overall FY26 Guidance

• Expect mid-teen revenue growth

• EBITDA margin to remain above 30%

• Healthy order book for CRAMS and APIs

• Disciplined capex for sustainable long-term growth

✅ Conclusion: Divi’s Laboratories Shows Strong Momentum in Q2 FY26

Divi’s Laboratories’ Q2 FY 2025-26 performance highlights the company’s resilience and strategic strength in the global pharmaceutical landscape. With:

✅ Strong revenue growth
✅ Marginal expansion
✅ Steady export demand
✅ Solid CRAMS pipeline
✅ Cost efficiency
✅ Debt-free balance sheet

Divi’s remains one of India’s best-positioned pharma exporters for long-term growth.

With global outsourcing increasing and API demand stabilizing, the company’s fundamentals remain robust and future-ready.